| Ticker | Current Price | % Daily Change | Volume (1,000s) | Average Volumn (1,000s) | Market Cap (Millions) | 1/2/2024 Price | % Change Since Inception 1/2/2024 |
|---|---|---|---|---|---|---|---|
| EPIX | $1.82 | -3.704% | 115 | 1,027 | $81 | $6.45 | -71.8% |
ESSA Pharma Inc.
999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada
ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386, represents a new approach to disrupting androgen receptor signaling pathway, the primary driver of prostate cancer growth.